- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 869KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 58KB)
Palbociclib – July 2021
Palbociclib: Tablet 75 mg, Tablet 100 mg, Tablet 125 mg; Ibrance®
Last updated
29 October 2021